Exelixis Inc
(NAS:EXEL)
$
36.115
0.265 (0.74%)
Market Cap: 10.31 Bil
Enterprise Value: 9.21 Bil
PE Ratio: 23.15
PB Ratio: 4.54
GF Score: 91/100 
Exelixis Inc at RBC Capital Markets Healthcare Conference Transcript
May 21, 2019 / 07:05PM GMT
Release Date Price:
$20.43
(+4.18%)
Kennen B. MacKay
RBC Capital Markets, LLC, Research Division - Co-Head of Biotechnology Research
Kennen MacKay, I'm one of the biotechnology analysts here at RBC, and it's my great pleasure to be joined by Exelixis. Up on stage here, I'm joined with Mike Morrissey, the CEO of Exelixis; as well as Chris Senner, EVP and CFO. Thanks so much for joining us. So before we dive into Q&A and sort of a fireside chat format here, maybe you can just give us sort a brief update in terms of where Exelixis is today and sort of...
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Yes, for sure.
Kennen B. MacKay
RBC Capital Markets, LLC, Research Division - Co-Head of Biotechnology Research
Where the ambitions are to be a year and 5 years from now?
Michael M. Morrissey;Kennen B. MacKay
Exelixis, Inc. - CEO, President & Director;RBC Capital Markets, LLC, Research Division - Co-Head of Biotechnology
How much time do I have?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers